Wealthfront Advisers
WST icon

Wealthfront Advisers’s West Pharmaceutical WST Stock Holding History

Wealthfront Advisers’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31M Buy
6,440
+937
+17% +$286K ﹤0.01% 586
2026
Q1 		$1.38M Buy
5,503
+24
+0.4% +$5.97K ﹤0.01% 663
2025
Q4 		$1.51M Buy
5,479
+1,007
+23% +$275K ﹤0.01% 638
2025
Q3 		$1.17M Buy
4,472
+1,765
+65% +$429K ﹤0.01% 670
2025
Q2 		$592K Sell
2,707
-864
-24% -$185K ﹤0.01% 769
2025
Q1 		$799K Sell
3,571
-1,109
-24% -$306K ﹤0.01% 703
2024
Q4 		$1.53M Buy
4,680
+1,065
+29% +$335K ﹤0.01% 582
2024
Q3 		$1.09M Sell
3,615
-659
-15% -$202K ﹤0.01% 629
2024
Q2 		$1.41M Sell
4,274
-2,345
-35% -$829K ﹤0.01% 560
2024
Q1 		$2.62M Sell
6,619
-1,701
-20% -$629K 0.01% 416
2023
Q4 		$2.93M Buy
8,320
+3,520
+73% +$1.25M 0.01% 369
2023
Q3 		$1.8M Buy
4,800
+59
+1% +$22.8K 0.01% 443
2023
Q2 		$1.81M Sell
4,741
-25
-0.5% -$8.93K 0.01% 439
2023
Q1 		$1.65M Buy
4,766
+593
+14% +$173K 0.01% 446
2022
Q4 		$982K Buy
4,173
+800
+24% +$190K ﹤0.01% 513
2022
Q3 		$830K Sell
3,373
-2,655
-44% -$809K ﹤0.01% 509
2022
Q2 		$1.82M Sell
6,028
-752
-11% -$245K 0.01% 401
2022
Q1 		$2.79M Buy
6,780
+1,011
+18% +$396K 0.01% 324
2021
Q4 		$2.71M Sell
5,769
-197
-3% -$84.8K 0.01% 326
2021
Q3 		$2.53M Buy
5,966
+77
+1% +$32.5K 0.01% 293
2021
Q2 		$2.12M Sell
5,889
-366
-6% -$121K 0.01% 292
2021
Q1 		$1.76M Buy
6,255
+1,296
+26% +$371K 0.01% 298
2020
Q4 		$1.41M Buy
4,959
+934
+23% +$262K 0.01% 301
2020
Q3 		$1.11M Buy
4,025
+682
+20% +$180K 0.01% 305
2020
Q2 		$759K Buy
+3,343
New +$657K 0.01% 364

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wealthfront Advisers's WST Position: Q2 2026 in Review

Wealthfront Advisers increased its West Pharmaceutical (WST) stake by 17% in Q2 2026, buying an estimated $286K and bringing the position to 6,440 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #586.

Wealthfront Advisers first reported a position in WST in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.93M in Q4 2023. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Wealthfront Advisers held 6,440 shares of West Pharmaceutical worth $2.31M as of Q2 2026.
  • Wealthfront Advisers bought 937 West Pharmaceutical shares in Q2 2026, an estimated $286K.
  • West Pharmaceutical made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #586 holding.
  • Wealthfront Advisers first reported a position in West Pharmaceutical in Q2 2020 and has held it in 25 quarters since.
  • Wealthfront Advisers's West Pharmaceutical position peaked at $2.93M in Q4 2023.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.